Title: The gemfibrozil cost-benefit model
Subjects: Coronary heart disease, Treatment, Medicaid, Prevention, Statistics, Economics, Gemfibrozil, Therapeutic use, Cost effectiveness, Digoxin, Mathematical models, Hyperlipidemia, Costs, Coronary Disease, Risk factors, Cost-Benefit Analysis, Drug therapy
Places: California, Finland, United States